Investigational drug · Phase 2
Carboplatin AUC-5
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
981
Any phase or sponsor naming "Carboplatin AUC-5"
First trial start
2019
Dec 10, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Carboplatin AUC-5", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Non-Small Cell Lung Cancer
- Head and Neck Cancer
- Melanoma
- Gastric Cancer
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Resectable Non-Small-Cell Lung Cancer
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Adult Solid Tumor
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Stomach and esophageal cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Carboplatin AUC-5" as an intervention, largest first.
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube CancerPivotal-lookingCompleted
AGO Study GroupAcademic, hospital or other
NCT00052468 · 1,742 participants · Start Aug 2002 · Primary completion Jul 2009
Drug: TCG; TC · For: Fallopian Tube Cancer; Ovarian Cancer
Sites: Copenhagen, Denmark; Paris, France; Bremen, Germany · 17 sites in all
- TCb vs EC-T in High Risk ER+/HER2- Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05901428 · 1,736 participants (planned) · Start Jun 1, 2023 · Primary completion Jun 2029
Drug: Docetaxel; Carboplatin and 2 more · For: Hormone Receptor Positive HER-2 Negative Breast Cancer
Sites: Shanghai, China
- ICON8: Weekly Chemotherapy in Ovarian CancerPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT01654146 · 1,485 participants (planned) · Start Jun 2011 · Primary completion Jun 2017
Drug: Carboplatin; Carboplatin and 2 more · For: Ovarian Cancer
Sites: London, United Kingdom
- A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingNot yet recruiting
Shanghai Henlius BiotechIndustry
NCT07865910 · 1,438 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 30, 2030
Drug: Investigational drug: HLX37 dose1, IV, Q3W; PEMBROLIZUMAB (alone or when added to a regimen above) and 4 more · For: NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Hefei, China; Beijing, China; Chongqing, China · 16 sites in all
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06780826 · 1,430 participants (planned) · Start Aug 28, 2024 · Primary completion Jun 30, 2025
Drug: Atezolizumab; Etoposide and 1 more · For: Lung Cancer, Small Cell
Sites: Shanghai, China
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03740165 · 1,367 participants · Start Dec 18, 2018 · Primary completion Aug 26, 2024
Drug: Pembrolizumab; Placebo for pembrolizumab and 6 more · For: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Sites: Birmingham, Alabama; Tucson, Arizona; Burbank, California · 227 sites in all
- De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy InductionPivotal-lookingRecruiting
Intergroupe Francophone de Cancerologie ThoraciqueAcademic, hospital or other
NCT05255302 · 1,360 participants (planned) · Start May 2, 2022 · Primary completion May 2025
Drug: Pembrolizumab before randomization; Chemotherapy and 2 more · For: Metastatic NSCLC
Sites: Aix-en-Provence, France; Amiens, France; Angers, France · 44 sites in all
- Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AlonePivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01450761 · 1,351 participants · Start Dec 13, 2011 · Primary completion Mar 19, 2015
Drug: Ipilimumab; Placebo matching Ipilimumab and 3 more · For: Small Cell Lung Carcinoma
Sites: Hot Springs, Arkansas; Auburn, California; La Jolla, California · 225 sites in all
- Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05687266 · 1,350 participants · Start Dec 29, 2022 · Primary completion Nov 1, 2027
Drug: Datopotamab deruxtecan; Durvalumab and 5 more · For: NSCLC
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 254 sites in all
- Sacituzumab Govitecan in Primary HER2-negative Breast CancerPivotal-lookingActive, not recruiting
GBG Forschungs GmbHAcademic, hospital or other
NCT04595565 · 1,332 participants (planned) · Start Oct 28, 2020 · Primary completion Mar 30, 2027
Drug: Capecitabine; Carboplatin and 2 more · For: HER2-negative Breast Cancer; Triple Negative Breast Cancer
Sites: Graz, Austria; Innsbruck, Austria; Linz, Austria · 163 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Quality of Life Outcomes From the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK-Mutated Non-Small-Cell Lung Cancer.
Kang EJ, Park S, Kim TM, et al. · Cancer Med 2026
- Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ࣙ50%: The PERSEE randomized phase III trial (GFPC 01-2020).
Descourt R, Mogenet A, Consigny M, et al. · Ann Oncol 2026
- Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Konecny GE, Lim PC, Santin AD, et al. · Clin Cancer Res 2026
- Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
Levy B, Paz-Ares L, Lin CC, et al. · J Thorac Oncol 2026
- CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomas.
Zhang S, Ozer BH, Omuro A, et al. · Neurooncol Adv 2026
- Very rare myoepithelial carcinoma occurred in the humerus: a case report.
Furuta T, Sakuda T, Yoshioka K, et al. · Int J Surg Case Rep 2026
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.